Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Accumulated Expenses: 2022-2025

Historic Accumulated Expenses for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to $48.2 million.

  • Day One Biopharmaceuticals' Accumulated Expenses rose 37.00% to $48.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.2 million, marking a year-over-year increase of 37.00%. This contributed to the annual value of $68.6 million for FY2024, which is 158.73% up from last year.
  • As of Q3 2025, Day One Biopharmaceuticals' Accumulated Expenses stood at $48.2 million, which was up 9.24% from $44.1 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Accumulated Expenses registered a high of $87.1 million during Q2 2024, and its lowest value of $7.3 million during Q1 2022.
  • In the last 3 years, Day One Biopharmaceuticals' Accumulated Expenses had a median value of $35.2 million in 2024 and averaged $39.6 million.
  • In the last 5 years, Day One Biopharmaceuticals' Accumulated Expenses spiked by 346.09% in 2024 and then plummeted by 49.32% in 2025.
  • Over the past 4 years, Day One Biopharmaceuticals' Accumulated Expenses (Quarterly) stood at $15.9 million in 2022, then soared by 66.29% to $26.5 million in 2023, then skyrocketed by 158.73% to $68.6 million in 2024, then surged by 37.00% to $48.2 million in 2025.
  • Its Accumulated Expenses was $48.2 million in Q3 2025, compared to $44.1 million in Q2 2025 and $43.6 million in Q1 2025.